Clinical Trials
33 trialsCIML NK Cells With Venetoclax for AML
Dana-Farber Cancer Institute
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Dana-Farber Cancer Institute
Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R
City of Hope Medical Center
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents
Instituto de Investigación Hospital Universitario La Paz
Interleukin-2 in Treating Patients With Myelodysplastic Syndrome
University of Washington
Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.
Masonic Cancer Center, University of Minnesota
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Masonic Cancer Center, University of Minnesota
Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML
Masonic Cancer Center, University of Minnesota
Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia
Cytovia, Inc.
Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG
M.D. Anderson Cancer Center
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia
Children's Oncology Group
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
National Cancer Institute (NCI)
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia
National Cancer Institute (NCI)
Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia
National Cancer Institute (NCI)
Interleukin-2 in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
European Organisation for Research and Treatment of Cancer - EORTC
High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
Roswell Park Cancer Institute
Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma
Roger Williams Medical Center
Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer
Hoag Memorial Hospital Presbyterian
Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer
Fred Hutchinson Cancer Center
Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Fred Hutchinson Cancer Center
Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia
Fred Hutchinson Cancer Center
Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous Leukemia
Fred Hutchinson Cancer Center
Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Elam02
Assistance Publique - Hôpitaux de Paris